MDXG · Mimedx Group, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $58.99M | - | $113.72M | $98.61M | $88.20M | - | $84.06M | $87.21M | $84.71M | - |
| Cost of Revenue | $17.37M | - | $18.72M | $18.68M | $16.56M | - | $15.32M | $14.86M | $12.99M | - |
| Gross Profit | $41.62M | - | $95.01M | $79.92M | $71.65M | - | $68.73M | $72.35M | $71.72M | - |
| R&D | $4.14M | - | $3.70M | $3.30M | $3.33M | - | $2.92M | $3.01M | $2.84M | - |
| SG&A | $53.23M | - | $69.00M | $64.15M | $59.97M | - | $53.52M | $55.40M | $55.13M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $528.0K | - | $572.0K | $558.0K | $558.0K | - | - | - | $558.0K | - |
| Operating Income | ($16.05M) | - | $22.19M | $12.37M | $8.25M | - | $11.16M | $23.45M | $13.20M | - |
| Interest Expense | $402.0K | - | $521.0K | $522.0K | $2.37M | - | - | - | - | - |
| Income Tax | ($4.47M) | - | $6.10M | $3.39M | $1.59M | - | $3.54M | $5.59M | $2.35M | - |
| Net Income | ($10.86M) | - | $16.75M | $9.62M | $7.02M | - | $8.10M | $17.63M | $9.26M | - |
| EPS - Basic | ($0.07) | - | $0.11 | $0.07 | $0.05 | - | $0.05 | $0.12 | $0.06 | - |
| EPS - Diluted | ($0.07) | - | $0.11 | $0.06 | $0.05 | - | $0.05 | $0.12 | $0.06 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $159.77M | $166.12M | $142.08M | $118.87M | $106.43M | $104.42M | $88.80M | $69.04M | $48.49M | $82.00M |
| Accounts Receivable | $46.03M | $75.71M | $78.19M | $69.23M | $62.29M | $55.83M | $54.03M | $52.80M | $57.02M | $53.87M |
| Inventory | $26.23M | $25.34M | $26.50M | $24.89M | $24.07M | $23.81M | $24.25M | $25.06M | $24.45M | $21.02M |
| Accounts Payable | $11.46M | $14.53M | $11.41M | $8.50M | $8.87M | $7.41M | $6.92M | $7.60M | $9.70M | $9.05M |
| Current Assets | $240.33M | $277.47M | $254.09M | $220.88M | $200.11M | $191.89M | $172.14M | $154.02M | $138.85M | $164.26M |
| Total Assets | $308.68M | $342.65M | $318.99M | $291.11M | $270.42M | $263.92M | $243.89M | $230.18M | $221.68M | $239.05M |
| Current Liabilities | $44.55M | $64.27M | $57.68M | $50.29M | $42.62M | $45.59M | $41.94M | $40.01M | $42.22M | $46.01M |
| Long-term Debt | $16.09M | $16.47M | $16.84M | $17.21M | $17.53M | $17.83M | $18.02M | $18.25M | $18.45M | $48.10M |
| Total Liabilities | $65.74M | $86.11M | $80.04M | $74.48M | $67.64M | $70.81M | $62.88M | $62.14M | $65.95M | $96.33M |
| Stockholders' Equity | $242.94M | $256.55M | $238.95M | $216.62M | $202.78M | $193.11M | $181.01M | $168.04M | $155.73M | $142.72M |
| Retained Earnings | ($53.54M) | ($42.68M) | ($57.87M) | ($74.62M) | ($84.24M) | ($91.26M) | ($98.70M) | ($106.79M) | ($124.42M) | ($133.68M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.88M | - | - | - | $5.30M | - | - | - | $5.98M | - |
| Investing Cash Flow | ($5.64M) | - | - | - | ($406.0K) | - | - | - | ($6.02M) | - |
| Financing Cash Flow | ($2.58M) | - | - | - | ($2.88M) | - | - | - | ($33.47M) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 70.6% | - | 83.5% | 81.1% | 81.2% | - | 81.8% | 83.0% | 84.7% | - |
| Operating margin | -27.2% | - | 19.5% | 12.5% | 9.4% | - | 13.3% | 26.9% | 15.6% | - |
| EBITDA margin | -26.3% | - | 20.0% | 13.1% | 10.0% | - | - | - | 16.2% | - |
| Net margin | -18.4% | - | 14.7% | 9.8% | 8.0% | - | 9.6% | 20.2% | 10.9% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 7.0% | - | 3.3% | 3.3% | 3.8% | - | 3.5% | 3.5% | 3.4% | - |
| SG&A / Revenue | 90.2% | - | 60.7% | 65.1% | 68.0% | - | 63.7% | 63.5% | 65.1% | - |
| Effective tax rate | - | - | 26.7% | 26.1% | 18.5% | - | 30.4% | 24.1% | 20.2% | - |
| Return on assets | -3.5% | - | 5.3% | 3.3% | 2.6% | - | 3.3% | 7.7% | 4.2% | - |
| Return on equity | -4.5% | - | 7.0% | 4.4% | 3.5% | - | 4.5% | 10.5% | 5.9% | - |
| Return on invested capital | -4.9% | - | 6.4% | 3.9% | 3.1% | - | 3.9% | 9.6% | 6.0% | - |
| Liquidity | ||||||||||
| Current ratio | 5.39 | 4.32 | 4.41 | 4.39 | 4.70 | 4.21 | 4.10 | 3.85 | 3.29 | 3.57 |
| Quick ratio | 4.81 | 3.92 | 3.95 | 3.90 | 4.13 | 3.69 | 3.53 | 3.22 | 2.71 | 3.11 |
| Cash ratio | 3.59 | 2.58 | 2.46 | 2.36 | 2.50 | 2.29 | 2.12 | 1.73 | 1.15 | 1.78 |
| Leverage | ||||||||||
| Debt / Equity | 0.07 | 0.06 | 0.07 | 0.08 | 0.09 | 0.09 | 0.10 | 0.11 | 0.12 | 0.34 |
| Debt / Assets | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | 0.08 | 0.20 |
| Debt / EBITDA | - | - | 0.74 | 1.33 | 1.99 | - | - | - | 1.34 | - |
| Interest coverage | -39.9x | - | 42.6x | 23.7x | 3.5x | - | - | - | - | - |
| Equity multiplier | 1.27 | 1.34 | 1.33 | 1.34 | 1.33 | 1.37 | 1.35 | 1.37 | 1.42 | 1.67 |
| Liabilities / Assets | 0.21 | 0.25 | 0.25 | 0.26 | 0.25 | 0.27 | 0.26 | 0.27 | 0.30 | 0.40 |
| Efficiency | ||||||||||
| Asset turnover | 0.19 | - | 0.36 | 0.34 | 0.33 | - | 0.34 | 0.38 | 0.38 | - |
| Inventory turnover | 0.66 | - | 0.71 | 0.75 | 0.69 | - | 0.63 | 0.59 | 0.53 | - |
| Days sales outstanding | 285d | - | 251d | 256d | 258d | - | 235d | 221d | 246d | - |
| Days inventory outstanding | 551d | - | 517d | 486d | 531d | - | 578d | 616d | 687d | - |
| Days payable outstanding | 241d | - | 223d | 166d | 195d | - | 165d | 187d | 273d | - |
| Cash conversion cycle | 595d | - | 545d | 577d | 593d | - | 647d | 650d | 660d | - |
| Valuation | ||||||||||
| P / E | - | - | 63.5x | 101.8x | 152.0x | - | 118.2x | 57.8x | 128.3x | - |
| P / B | 2.4x | - | 4.4x | 4.2x | 5.6x | - | 4.8x | 6.1x | 7.4x | - |
| P / S | 9.9x | - | 9.2x | 9.3x | 12.9x | - | 10.4x | 11.8x | 13.6x | - |
| EV / EBITDA | - | - | 40.4x | 62.7x | 119.0x | - | - | - | 81.8x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -33.1% | - | 35.3% | 13.1% | 4.1% | - | 2.9% | 7.3% | 18.2% | - |
| Revenue CAGR (3y) | -6.3% | - | 18.9% | 13.8% | 14.4% | - | 10.0% | 8.6% | 12.2% | - |
| Revenue CAGR (5y) | -0.3% | - | 12.1% | 12.9% | 7.4% | - | - | - | - | - |
| Gross profit growth (YoY) | -41.9% | - | 38.2% | 10.5% | -0.1% | - | 2.7% | 6.9% | 21.0% | - |
| Operating income growth (YoY) | - | - | 98.8% | -47.2% | -37.5% | - | 3.2% | 741.1% | - | - |
| Net income growth (YoY) | - | - | 106.9% | -45.4% | -24.2% | - | -5.1% | 1368.8% | - | - |
| EPS growth (YoY) | - | - | 120.0% | -50.0% | -16.7% | - | -16.7% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 19.8% | 32.9% | 32.0% | 28.9% | 30.2% | 35.3% | 13509.6% | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$418.63M totalWound$276.33M · 66.0%
Surgical$142.30M · 34.0%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing MIMEDX GROUP against the 5 most active filers in the same SIC group.